By simulating various scenarios, predictive models help public health officials weigh the trade-offs between different ...

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

Now is the time for policy makers, payers, health systems, and clinicians to act decisively by extending AHCaH, evaluating ...

Massachusetts’ new health care reform expands the authority of the state to intervene prior to significant changes to the ...

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

The Guiding an Improved Dementia Experience (GUIDE) model could be further strengthened by enhancements and clarifications of ...

During the COVID-19 pandemic, suppression of scientific debate and the marginalization of dissenting voices weakened public ...

As health scholars at the American Enterprise Institute, the Brookings Institution, and the Bipartisan Policy Center, we ...

Health Affairs' Senior Deputy Editor Rob Lott interviews Eric Topol, Executive Vice President of Scripps Research, on his new ...

By May 5, 2025, the Trump administration will file its first brief in Missouri v. Food and Drug Administration, staking out a ...

Early detection of rare but treatable diseases has long been one of public health’s quiet triumphs, sparing thousands of ...

Unless Congress acts to renew them by the end of this year, enhanced premium subsidies for the Affordable Care Act’s ...